Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • Saudi Medical Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Neurosciences Journal
  • Other Publications
    • Saudi Medical Journal
  • My alerts
  • Log in
Neurosciences Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Case ReportCase Report
Open Access

Safety of tissue plasminogen activator factor in an acute stroke patient with two unruptured cerebral aneurysms

Ali M. Sonbaa, Alaa F. Khayat and Mohammed A. Almekhlafi
Neurosciences Journal October 2018, 23 (4) 334-337; DOI: https://doi.org/10.17712/nsj.2018.4.20180054
Ali M. Sonbaa
From the Division of Neurology, Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alaa F. Khayat
From the Division of Neurology, Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
MBBS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammed A. Almekhlafi
From the Division of Neurology, Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
MSc, FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

It is estimated that 6.6%-9.3% of stroke patients have unruptured cerebral aneurysms. The safety of recombinant tissue plasminogen activator (r-tPA) for stroke patients with these aneurysms is uncertain. We report the case of a 58-year old male presented with an acute ischemic stroke within 2 hours of symptom onset and was treated with r-tPA. Further investigation showed that the patient had 2 unruptured cerebral aneurysms. He recovered completely from the stroke and was discharged home in a few days with no deficits. Although cerebral aneurysms are considered a relative contraindication for r-tPA, our case provides evidence that it can be safely administered to these patients.

The use of thrombolytic agents in treating stroke patients with incidental cerebral aneurysms is controversial. The number of stroke patients described as having unruptured intracranial aneurysms ranges from 6.6-9.3%.1 Reports and studies suggest that thrombolytic agents such as recombinant tissue plasminogen activator (r-tPA) are safe in these patients.2,3 Based on the available literature, the historical risk estimation for aneurysmal bleeding after receiving intravenous thrombolytics for acute ischemic stroke with cerebral aneurysm is approximately 5.7% (Figure 1).4 Most of the studies focused on the treatment methods and outcomes, but not on the presence of aneurysmal risk factors such as hypertension, smoking, or a family history of aneurysm or subarachnoid hemorrhage.1,5,6 In addition to chronic diseases, these factors can play a role in aneurysmal rupture and hemorrhage after using r-tPA. Our objective is to report the case of an acute ischemic stroke patient who safely received intravenous r-tPA and was later found to have 2 incidental cerebral aneurysms, demonstrating the safety of r-tPA among these patients. We also aim to review the literature to explore the safety of r-tPA and how clinicians can estimate the risk of an aneurysmal rupture hemorrhage.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

The total number of stroke patients who had hemorrhages after administration of r-tPA, including those who had cerebral aneurysms.

Case Report

Patient information

A 58-year old Eritrean African black man was known to be hypertensive and dyslipidemic and had undergone a coronary artery stenting 3 weeks prior to his presentation. He presented to the Emergency Department complaining of weakness and aphasia.

Clinical findings

The patient had significant sudden onset weakness for the past 2 hours on the right side of his body, more so in his face and arm than in his leg. He had expressive aphasia but was able to follow simple commands. He was rated an 11 on the National Institute of Health Stroke Scale.

Diagnostic assessment

An emergency computed tomography (CT) scan was performed which showed no evidence of hemorrhage or other acute changes.

Therapeutic intervention

After discussing with the patient’s family and receiving consent, 65 mg of intravenous r-tPA was administered at the beginning, 3 hours after the time of onset. After starting the r-tPA, the patient was rushed for a CT angiogram that showed a distal branch occlusion of the left middle cerebral artery (Figure 2A). In addition, there were 2 cerebral aneurysms: one 5-mm pericallosal aneurysm (Figure 2B) and one 2-mm middle-cerebral artery bifurcation aneurysm (Figure 2C). Because these were believed to be incidentally discovered, r-tPA was continued and the patient was admitted to the intensive care unit.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

CT angiography scans of patient’s brain performed after starting the r-tPA A) Computed tomography (CT) angiography of a distal branch occlusion of the middle cerebral artery; B) CT angiography of a 2-mm middle cerebral artery bifurcation aneurysm; C) CT angiography of a 5-mm pericallosal aneurysm.

Follow-up and outcomes

The neurological examination on the next day showed complete resolution of the initial deficits, with no complaints by the patient of headache or other neurological symptoms. A 24-h CT scan of the head showed no hemorrhagic transformation or subarachnoid hemorrhage. He was discharged home on Day 3 in a normal state with an elective plan for follow-up.

Discussion

Because it affects the outcome, time is extremely sensitive in the management of acute ischemic stroke patients. The most feared complication of administering r-tPA is intracranial hemorrhage, which is estimated to occur in 0.3%-6.4% of cases.5,7,8 In the majority of cases, the benefits of therapy outweigh the risks when given within 4.5 hours of onset or last-seen well time. However, there are circumstances in which r-tPA use poses a significant risk and is thus contraindicated. These include the presence of an intracranial hemorrhage or large subacute stroke and uncontrolled hypertension at the time of presentation that is not responding to intravenous blood pressure-lowering agents. However, there are perceived absolute contraindications that have not actually been proven with data.9 One of these is the presence of incidental unruptured brain aneurysms.

There is a good body of literature reporting on the safety of r-tPA in patients with incidental brain aneurysms. However, there are variations among the case reports (Table 1) and analytic reviews (Table 2) such as the thrombolytic agent, aneurysm size and site, and the existence of co-morbidities and risk factors of intracerebral hemorrhage that is related to thrombolysis. These risk factors include hypertension, smoking, alcohol consumption, a family history of aneurysm or subarachnoid hemorrhage, advanced age of the patient, thrombolytic dosage, hyperfibrinogenemia, increased prothrombin time, thrombocytopenia, hyperglycemia, and delayed treatment.1,5,6

View this table:
  • View inline
  • View popup
Table 1

Analysis of previous case reports.

View this table:
  • View inline
  • View popup
Table 2

Analysis of previous systemic studies.

Thrombolytic therapy may provoke aneurysm rupture by one of the following mechanisms: (1) increasing turbulence within the sac though hemodynamic changes or (2) increasing the flow within the aneurysm by dissolving a clot in the aneurysm dome.5 Yet, the use of r-tPA is an effective method for acute ischemic stroke treatment.5 Some of the r-tPA-related hemorrhages in patients with brain aneurysms were at the site of infarction but not due to aneurysmal rupture.4 A careful evaluation of the aneurysm’s size and site must be made to assess the risk of rupture. In addition, other medical conditions can be associated with an increased risk of rupture that are independent of the presenting stroke or r-tPA usage.1 The presence of co-morbidities plays a major role in aneurysmal rupture, first because they have an impact on the pathological vascular changes, and second, in the absence of stroke, the co-morbidities will be under consideration while evaluating the aneurysm for its risk of rupturing. Most of the reported cases with a ruptured aneurysm or hemorrhagic event had a co-existing chronic medical condition. Aneurysms can only be diagnosed by a CT angiogram, and the majority of stroke patients in Kingdom of Saudi Arabia do not receive them. Despite that, subarachnoid hemorrhage after r-tPA administration is very rare, which means that r-tPA is safe in these patients.

In conclusion, According to the available evidence, treating acute ischemic stroke patients with incidental unruptured aneurysms by r-tPA appears to be safe. A careful CT-scan assessment of stroke patients and an evaluation of the risk of aneurysmal rupture is important when CT angiography reveals brain aneurysms in the acute-stroke setting as in our case that is summarized in a timeline (Figure 3).

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Case report timeline.

Footnotes

  • Disclosure. The authors declare no conflicting interests, support or funding from any drug company.

  • Received January 29, 2018.
  • Accepted June 20, 2018.
  • Copyright: © Neurosciences

Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.

References

  1. ↵
    1. Haji F,
    2. van Adel B,
    3. Avery M,
    4. Megyesi J,
    5. Young GB
    (2014) Intracranial aneurysm rupture following intravenous thrombolysis for stroke. Can J Neurol Sci 41, 95–98.
  2. ↵
    1. Mittal MK,
    2. Seet RC,
    3. Zhang Y,
    4. Brown RD Jr.,
    5. Rabinstein AA
    (2013) Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms. J Stroke Cerebrovasc Dis 22, 639–643.
  3. ↵
    1. Edwards NJ,
    2. Kamel H,
    3. Josephson SA
    (2012) The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms:a case series and review of the literature. italic>Stroke 43, 412–416.
  4. ↵
    1. Wang HF,
    2. Chan CW,
    3. Chan HH,
    4. Hung HC
    (2013) Asymptomatic cerebral aneurysm in stroke patients eligible for intravenous thrombolytic therapy. Acta Neurol Taiwan 22, 43–48.
  5. ↵
    1. Lagares A,
    2. Gómez PA,
    3. Lobato RD,
    4. Alén JF,
    5. Campollo J,
    6. Benito-León J
    (1999) Cerebral aneurysm rupture after r-TPA thrombolysis for acute myocardial infarction. Surg Neurol 52, 623–626.
  6. ↵
    1. D'Olhaberriague L,
    2. Joshi N,
    3. Chaturvedi S,
    4. Mitsias P,
    5. Coplin W,
    6. Lewandowski CA,
    7. et al.
    (2000) Tissue plasminogen activator for acute ischemic stroke in patients with unruptured cerebral aneurysms. J Stroke Cerebrovasc Dis 9, 181–184.
  7. ↵
    1. Rammos SK,
    2. Neils DM,
    3. Fraser K,
    4. Klopfenstein JD
    (2012) Anterior communicating artery aneurysm rupture after intravenous thrombolysis for acute middle cerebral artery thromboembolism:case report. Neurosurgery 70, 1603–1607.
  8. ↵
    1. Kane I,
    2. Sandercock P,
    3. Thomas B
    (2005) Can patients with unruptured intracranial aneurysms be treated with thrombolysis?Cerebrovasc Dis, 20, 51–52.
  9. ↵
    1. Demaerschalk BM,
    2. Kleindorfer DO,
    3. Adeoye OM,
    4. Demchuk AM,
    5. Fugate JE,
    6. Grotta JC,
    7. et al.
    (2016) Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke:A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 47, 581–641.
PreviousNext
Back to top

In this issue

Neurosciences Journal: 23 (4)
Neurosciences Journal
Vol. 23, Issue 4
1 Oct 2018
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Neurosciences Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety of tissue plasminogen activator factor in an acute stroke patient with two unruptured cerebral aneurysms
(Your Name) has sent you a message from Neurosciences Journal
(Your Name) thought you would like to see the Neurosciences Journal web site.
Citation Tools
Safety of tissue plasminogen activator factor in an acute stroke patient with two unruptured cerebral aneurysms
Ali M. Sonbaa, Alaa F. Khayat, Mohammed A. Almekhlafi
Neurosciences Journal Oct 2018, 23 (4) 334-337; DOI: 10.17712/nsj.2018.4.20180054

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Safety of tissue plasminogen activator factor in an acute stroke patient with two unruptured cerebral aneurysms
Ali M. Sonbaa, Alaa F. Khayat, Mohammed A. Almekhlafi
Neurosciences Journal Oct 2018, 23 (4) 334-337; DOI: 10.17712/nsj.2018.4.20180054
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Unmasking the mimic: Leprosy neuropathy misdiagnosed as chronic inflammatory demyelinating polyneuropathy: A case report from Saudi Arabia
  • Seminal vesicle schwannoma with chronic hemorrhage
  • Marchiafava-Bignami disease post-bariatric surgery: A case report and review of similar cases
Show more Case Report

Similar Articles

Navigate

  • home

More Information

  • Help

Additional journals

  • All Topics

Other Services

  • About

© 2025 Neurosciences Journal Neurosciences is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3183. Print ISSN 1319-6138.

Powered by HighWire